Loading organizations...
§ Venture Capital · Kagoshima, Japan
Venture capital firm investing in biotechnology startups focused on nucleic acid therapeutics and genetic medicines.
Kagoshima Shinsangyo Sosei Investment LP is a venture capital firm focused on early-stage investments in biotechnology startups developing nucleic acid therapeutics and genetic medicines for rare diseases. The firm notably co-led an $18 million Series A financing round for portfolio company WAVE Life Sciences in February 2015, and subsequently participated in the company's $66 million Series B financing in August 2015. These investments supported the development of innovative genetic medicines, with RA Capital Management also co-leading the Series A and SNBL Ltd. having provided earlier seed funding to WAVE Life Sciences. WAVE Life Sciences, a key portfolio company, was co-founded by Gregory Verdine and Takeshi Wada. Further details regarding Kagoshima Shinsangyo Sosei Investment LP's own founding year or its founders are not publicly available.
Kagoshima Shinsangyo Sosei Investment has 2 tracked investments across 1 company. The latest tracked deal is $66.0M Series B in Wave Life Sciences in August 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2015 | Wave Life Sciences | $66.0M Series B | Foresite Capital | Cormorant Asset Management, Fidelity Management & Research Company, Jennison Associates, NEW Leaf Venture Partners, RA Capital Management, Redmile Group |
| Feb 1, 2015 | Wave Life Sciences | $18.0M Series A | Kagoshima Shinsangyo Sosei Investment, Peter Kolchinsky | Snbl |